Login / Signup

Galantamine beyond Alzheimer's disease-a fact or artefact?

Ahmed NaguyKhaled HusainBibi Alamiri
Published in: CNS spectrums (2020)
Galantamine is US-Food and Drug Administration FDA-approved for mild-to-moderate Alzheimer's disease. However, its unique pharmacological portfolio speaks to the idea of a pluripotent agent with a broad therapeutic potential. Here, authors briefly discuss these off-label clinical indications synthesizing the extant evidence.
Keyphrases
  • drug administration
  • cognitive decline
  • risk assessment
  • mild cognitive impairment